Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, diabetes titan Novo Nordisk (NVO +0.04%) just received a credit rating upgrade from Moody's; already at Aa2, the company has been elevated to Aa1, which is only one grade away from Moody's ultimate Aaa rating. Motley Fool health care analyst Brenton Flynn highlights some of the new drugs that will contribute to NVO's solid growth.
